TY - JOUR
T1 - Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis
T2 - Association with disease severity
AU - Yoshizaki, Ayumi
AU - Komura, Kazuhiro
AU - Iwata, Yohei
AU - Ogawa, Fumihide
AU - Hara, Toshihide
AU - Muroi, Eiji
AU - Takenaka, Motoi
AU - Shimizu, Kazuhiro
AU - Hasegawa, Minoru
AU - Fujimoto, Manabu
AU - Sato, Shinichi
N1 - Funding Information:
Acknowledgment We thank Ms. Y. Yamada, M. Yozaki, A. Usui, and K. Shimoda for technical assistance. This work was supported by a grant of Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (to S. Sato).
PY - 2009/3
Y1 - 2009/3
N2 - Introduction: The high mobility group box 1 protein (HMGB-1)/advanced glycation end products (RAGE) system is recently shown to play an important part in immune/inflammatory disorders. However, the association of this system in systemic sclerosis (SSc) remains unknown. Materials and Methods: To determine clinical association of serum levels of HMGB-1 and soluble RAGE (sRAGE) in patients with SSc, sera from 70 patients with SSc and 25 healthy controls were examined by enzyme-linked immunosorbent assay. Sera from tight-skin mice and bleomycin-induced scleroderma mice, animal models for SSc, were also examined. Skin HMGB-1 and RAGE expression was assessed by immunohistochemistry. Results and Discussion: Serum HMGB-1 and sRAGE levels in SSc were higher than those in controls. Similarly, HMGB-1 and sRAGE levels in animal SSc models were higher than those in control mice. SSc patients with elevated HMGB-1 and sRAGE levels had more frequent involvement of several organs and immunological abnormalities compared to those with normal levels. Furthermore, HMGB-1 and sRAGE levels correlated positively with modified Rodnan total skin thickness score and negatively with pulmonary function test. Conclusions: HMGB-1 and sRAGE expression in the sclerotic skin was more intense than normal skin. These results suggest that elevated serum HMGB-1 and sRAGE levels are associated with the disease severity and immunological abnormalities in SSc.
AB - Introduction: The high mobility group box 1 protein (HMGB-1)/advanced glycation end products (RAGE) system is recently shown to play an important part in immune/inflammatory disorders. However, the association of this system in systemic sclerosis (SSc) remains unknown. Materials and Methods: To determine clinical association of serum levels of HMGB-1 and soluble RAGE (sRAGE) in patients with SSc, sera from 70 patients with SSc and 25 healthy controls were examined by enzyme-linked immunosorbent assay. Sera from tight-skin mice and bleomycin-induced scleroderma mice, animal models for SSc, were also examined. Skin HMGB-1 and RAGE expression was assessed by immunohistochemistry. Results and Discussion: Serum HMGB-1 and sRAGE levels in SSc were higher than those in controls. Similarly, HMGB-1 and sRAGE levels in animal SSc models were higher than those in control mice. SSc patients with elevated HMGB-1 and sRAGE levels had more frequent involvement of several organs and immunological abnormalities compared to those with normal levels. Furthermore, HMGB-1 and sRAGE levels correlated positively with modified Rodnan total skin thickness score and negatively with pulmonary function test. Conclusions: HMGB-1 and sRAGE expression in the sclerotic skin was more intense than normal skin. These results suggest that elevated serum HMGB-1 and sRAGE levels are associated with the disease severity and immunological abnormalities in SSc.
UR - http://www.scopus.com/inward/record.url?scp=61849089739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61849089739&partnerID=8YFLogxK
U2 - 10.1007/s10875-008-9252-x
DO - 10.1007/s10875-008-9252-x
M3 - Article
C2 - 18825489
AN - SCOPUS:61849089739
SN - 0271-9142
VL - 29
SP - 180
EP - 189
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
IS - 2
ER -